Farletzumab ELISA Kit

Farletuzumab (MORAb-003) is a humanized α-FR-targeted monoclonal antibody derived from the murine antibody, LK26 (Teng, Xie, Teng, & Lee, 2012) . In preclinical studies, farletuzumab elicited robust antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, thus inhibiting the growth of human ovarian tumor xenografts (Teng et al., 2012) . Farletuzumab combined with carboplatin and taxane may enhance the response rate and duration of response in patients with platinum-sensitive ovarian cancer with first relapse after remission duration of 6–18 months (Konner et al., 2010) . Based on these encouraging findings, a Phase III study was undertaken in patients with platinum-sensitive recurrent ovarian cancer (Walters et al., 2013) . The FAR131 trial did not prove efficacy for patients with platinum-sensitive ovarian cancer (PSOC, defined as a PFI of ≥ 6 months), in terms of the primary endpoint of PFS. Aside from Farletuzumab, other antibodies have been developed to target FR, and tested clinically. Similar to studies exploiting Vintafolide, a Phase III, open-label, randomized study (ClinicalTrials.gov Identifier: NCT02631876) was designed to compare the safety and efficacy of Mirvetuximab soravtansine, also known as IMGN853, an α-FR-targeting antibody-drug conjugate, to that of selected single-agent chemotherapies in women with platinum-resistant α-FR-positive advanced EOC, and other pelvic cancers. The antibody serves to specifically target the highly potent microtubule inhibitor maytansinoid DM4 to the α-FR-positive cancer cells. In addition, vaccines against FR have been produced and evaluated, such as the folate-binding protein vaccines E39 and J65 involved in the Phase Ib trial (ClinicalTrials.gov Identifier: NCT02019524) for patients with breast or ovarian cancer diagnosis who have been treated and are without evidence of disease. A Phase II clinical trial (NCT02764333) is testing on patients with Pt-resistant ovarian cancer the safety and effectiveness of two investigational drugs, TPIV200/huFR-1 (also called TPIV200), a vaccine consisting of proteins from α-FR mixed with GM-CSF, and durvalumab (MEDI4736) .

Farletuzumab

M3, MORAb-003, MORAb-003-VCP-eribulin, MORAb-202, CAS: 896723-44-7

Colorimetric

Quantitative

Plasma, Serum

0.31-5 μg/mL

80-120%

0.156 μg/ml

2-8 °C

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

For Research Use Only.